ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081
(Thomson Reuters ONE) -
Unternehmensinformation / Kurzprofil:Bereitgestellt von Benutzer: hugin
Datum: 22.12.2009 - 18:02 Uhr
Sprache: Deutsch
News-ID 10048
Anzahl Zeichen: 0
contact information:
Town:
Kategorie:
Diese Pressemitteilung wurde bisher
427 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...
GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...
GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...
